New chemo cocktail aims to outsmart aggressive myeloma

NCT ID NCT00869232

Ongoing Disease control Sponsor: University of Arkansas Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests a combination of eight chemotherapy drugs given in lower doses and shorter cycles to people with high-risk multiple myeloma. The goal is to prevent myeloma cells from regrowing between treatments, leading to longer remissions and better survival. The study enrolls 90 newly diagnosed patients with high-risk features.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a combination of chemotherapy drugs: Velcade, melphalan, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide
What this could lead to: If it works, this approach could lead to longer remissions and better survival for people with high-risk multiple myeloma.
What could go wrong: This is a phase II trial with only 90 participants, so results may not apply to everyone. The intensive chemo regimen also carries risks like infection and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.